Adding Neoadjuvant and Adjuvant Pembrolizumab to Standard Care Significantly Improves EFS Among Patients with Locally Advanced HNSCC By Ogkologos - July 7, 2025 481 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the KEYNOTE-689 study Source RELATED ARTICLESMORE FROM AUTHOR The Legacy of the ESMO Patient Engagement Summit 2025: Advancing Rights of Patients with Cancer via Cross-Border Best Practices and Collaboration Sustained PFS Benefit of Imlunestrant Over SoC in Patients with ESR1-mutated Advanced Breast Cancer ESMO Welcomes Launch of Health Package Introducing EU Measures That Can Boost Innovation in Oncology and Help Prevent New Cancer Cases MOST POPULAR Overall Breast Cancer Incidence Down Since 1999, Rates Increase for Women... January 18, 2022 2021 ASCO Annual Meeting: New Treatments and Research Advances in Esophageal... June 3, 2021 GreaterGood’s Mask Donations Are Helping LA Family Housing Keep Homeless People... October 26, 2020 Engaging People with Low-Grade Glioma in Cancer Research August 24, 2023 Load more HOT NEWS EMA Recommends Granting a Marketing Authorisation for Vorasidenib Largest Study on Frequent Aspirin Use Supports Reduction in Ovarian Cancer... Exploring Coping Resources to Help with Physical, Practical, and Emotional Challenges... Workout Wednesday – Upper Body Stretches
